GlaxoSmithKline Pharmaceuticals share news and announcements
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
GlaxoSmithKline Pharmaceuticals share news and announcements
721 announcements, routine notices left out, newest first. Page 15 of 15.
Feb 2008
22 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 33927 lacs for quarter ending on 31-DEC-2007 against Rs. 32027 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 8090 lacs for the quarter ending on 31-DEC-2007 against Rs. 6779 lacs for the quarter ending on 31-DEC-2006.22 Feb · Dividend
Board of Directors of the Company in its meeting held on February 22, 2008 have recommended the payment of a Dividend of Rs. 18/- per equity share for the year ended December 31, 2007. The Directors are also pleased to recommend a special additional dividend of Rs.18/- per equity share.22 Feb · Results
Consolidated Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 160820 lacs for year ending on 31-DEC-2007 against Rs. 158199 lacs for the year ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 54755 lacs for the year ending on 31-DEC-2007 against Rs. 55100 lacs for the year ending on 31-DEC-2006.22 Feb · Results
Standalone Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 157714 lacs for year ending on 31-DEC-2007 against Rs. 155292 lacs for the year ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 53766 lacs for the year ending on 31-DEC-2007 against Rs. 54551 lacs for the year ending on 31-DEC-2006.15 Feb · Board meeting
To consider, amongst other things, approval of the audited financial results for the year ended December 31, 2007 and to recommend dividend, if any, on the equity shares of the Company.
Jan 2008
3 Jan · Results
The Audited Results for the year ended 31st December 2007 are expected to be approved by our Board of Directors before the end of March 2008 i.e. within a period of three months from the close of accounting year and as such, we would be announcing the audited financial results within a period of three months of the close of the accounting year". " We will not be publishing the un-audited financial results for the quarter ended 31st December 2007.
Oct 2007
26 Oct · Management
Mr. Ronald C Sequeira has been appointed as an Executive Director in the casual vacancy caused by the resignation of Mr. A S Lakshmanan, Non-Executive Director, with effect from 25th October 200725 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 42080 lacs for quarter ending on 30-SEP-2007 against Rs. 39915 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 24901 lacs for the quarter ending on 30-SEP-2007 against Rs. 28543 lacs for the quarter ending on 30-SEP-2006.12 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the 3rd Quarter ended September 30, 2007.
Sep 2007
19 Sep · Results
The Shareholders, have, through Postal Ballot, approved the transfer, sale and the disposal of our Fine Chemical Business ["the QFC Undertaking"] to Thermo Electron LLS India Private Limited as a going concern on a slump sale basis for a lump sum consideration of Rs.240 crores, by an overwhelming majority of 99.984% voting in favour of the Resolution
Aug 2007
20 Aug · Change in Registrar & Share Transfer Agent
Karvy Computershare Private Limited have been appointed as Registrar and Share transfer Agent of the Company with effect from 1st September 2007 for rendering the entire range of services to our shareholders, as is provided by the current Registrar and Share Transfer Agent, GlaxoSmithKline Consumer Healthcare Limited. Shareholders are requested to address their queries to Karvy Computershare Private Limited at the following address from 1st September 2007. Karvy Computershare Private Limited, Unit: Glaxosmithkline Pharmaceuticals Limited, Plot No 17-24, Vittal Rao Nagar, Madhapur, Hyderabad - 500081, Tel No.: 040-23420818 / 23420828, Fax No.: 040-23420814, Contact Person: Mr. M R V Subramaniam / Satheesh H K
Jul 2007
26 Jul · Board meeting
July 26, 2007 that: "At a Board Meeting of the Company held today, the Board of Directors has approved the divestment of the Company's Fine Chemical Business ("QFC Undertaking") as a going concern to Thermo Electron LLS India Private Limited, a subsidiary of Thermo Fisher Scientific Inc., a leading American Company, for a total consideration of Rs.240 crores, subject to receipt of necessary approvals. The proposed divestment of the QFC Undertaking will transfer all rights and obligations of the Company in the QFC Undertaking. The Company will now proceed seeking the approval of its shareholders through a postal ballot. Subject to receipt of the Shareholders' consent and other requisite approvals, the transaction is expected to be completed by end September 2007".26 Jul · Results
Standalone Results for the half year ended on 30-JUN-2007 as follows: Net Sales of Rs. 81707 lacs for half year ending on 30-JUN-2007 against Rs. 83350 lacs for the half year ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 20775 lacs for the half year ending on 30-JUN-2007 against Rs. 19229 lacs for the half year ending on 30-JUN-2006.26 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 39561 lacs for quarter ending on 30-JUN-2007 against Rs. 40734 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 9643 lacs for the quarter ending on 30-JUN-2007 against Rs. 9106 lacs for the quarter ending on 30-JUN-2006.6 Jul · Board meeting
To consider amongst other things, approval of unaudited financial results for the half-year ended June 30, 2007.
May 2007
29 May · Meeting
Minutes of the Annual General Meetings of the Company held on March 30, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
11 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2007.
Feb 2007
19 Feb · Dividend
The dividend will be payable on or after 30th March 200716 Feb · Dividend
Board of Directors at their meeting held on February 16,2007, have recommended the payment of a Dividend of Rs. 17 per equity share for the year ended December 31,2006. The Directors have also recommended a special additional dividend of Rs. 14 per equity share.12 Feb · Corporate action
The Register of Members and Transfer Books of our Company will be closed from Friday, 16th March 2007 to Friday, 30th March 2007 (both days inclusive). All applications for transfer of shares received up to the close of business hours on Thursday, 15th March 2007 will be given effect and the dividend will be paid to the Beneficial owners12 Feb · Board meeting
To consider amongst other things, approval of the audited financial results for the year ended December 31,2006 and to recommend dividend, if any, on the equity shares of the Company.